Cite
Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
MLA
Sezaki, Hitomi, et al. “Initial- and Re-Treatment Effectiveness of Glecaprevir and Pibrentasvir for Japanese Patients with Chronic Hepatitis C Virus-Genotype 1/2/3 Infections.” Journal of Gastroenterology, vol. 54, no. 10, Oct. 2019, pp. 916–27. EBSCOhost, https://doi.org/10.1007/s00535-019-01575-9.
APA
Sezaki, H., Suzuki, F., Hosaka, T., Fujiyama, S., Kawamura, Y., Akuta, N., Kobayashi, M., Suzuki, Y., Saitoh, S., Arase, Y., Ikeda, K., Kobayashi, M., & Kumada, H. (2019). Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections. Journal of Gastroenterology, 54(10), 916–927. https://doi.org/10.1007/s00535-019-01575-9
Chicago
Sezaki, Hitomi, Fumitaka Suzuki, Tetsuya Hosaka, Shunichirou Fujiyama, Yusuke Kawamura, Norio Akuta, Masahiro Kobayashi, et al. 2019. “Initial- and Re-Treatment Effectiveness of Glecaprevir and Pibrentasvir for Japanese Patients with Chronic Hepatitis C Virus-Genotype 1/2/3 Infections.” Journal of Gastroenterology 54 (10): 916–27. doi:10.1007/s00535-019-01575-9.